Clonell Therapeutics

Clonell Therapeutics is an Australian biotechnology company dedicated to overcoming cancer relapse by targeting the specific cellular clones that survive initial therapy. Spun out from the Peter MacCallum Cancer Centre in Melbourne, the company leverages the pioneering research of founders Professor Mark Dawson and Professor Sarah-Jane Dawson in the fields of epigenetics and liquid biopsies. Clonell utilizes a proprietary platform combining single-cell lineage tracing and functional genomics to identify novel therapeutic targets within therapy-resistant cell populations. Their primary focus is on developing small molecule inhibitors that modulate epigenetic regulators to eradicate these "clonogenic" cells. Currently in the pre-clinical stage, the company aims to transform the treatment landscape for both hematological malignancies and solid tumors by ensuring more durable clinical responses.